Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma

Published:2018-08 Issue:8 Volume:24 Page:1602-1609
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Nieto Yago^ORCID,Thall Peter F.,Ma Junsheng,Valdez Benigno C.,Ahmed Sairah,Anderlini Paolo,Popat Uday,Jones Roy B.,Shpall Elizabeth J.,Hosing Chitra,Qazilbash Muzaffar,Kebriaei Partow,Alousi Amin,Timmons Melissa,Gulbis Alison,Myers Alan,Oki Yasuhiro,Fanale Michelle,Dabaja Bouthaina,Pinnix Chelsea,Milgrom Sarah,Champlin Richard,Andersson Borje S.

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference22 articles.

1. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial;Linch;Lancet,1993

2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial;Schmitz;Lancet,2002

3. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse;Sureda;Ann Oncol,2005

4. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma;Moskowitz;Blood,2010

5. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma;Bröckelmann;Ann Oncol,2017

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemcitabine‐based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non‐Hodgkin lymphoma: No difference in outcomes;Cancer Medicine;2024-01

2. Hematopoietic Cell Transplantation for Hodgkin Lymphoma;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

3. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant;Bone Marrow Transplantation;2023-05-18

4. Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy;Bone Marrow Transplantation;2023-03-25

5. The role of transplantation in Hodgkin lymphoma;Frontiers in Oncology;2023-01-26